At the 2023 Uromigos Live & Unplugged event, Karine Tawagi, MD, University of Illinois, discussed her proposed trial during the Rising Stars panel on a phase 2 multi-arm parallel trial for metastatic urothelial carcinoma examining standard-of-care chemotherapy versus sacituzumab for FGFR wild-type patients, and randomized FGFR inhibitors versus sacituzumab for patients with FGFR mutations.
Uromigos Live 2023: Dr. Karine Tawagi on Her Proposed Trial for Metastatic Urothelial Carcinoma
By Karine Tawagi, MD - Last Updated: November 8, 2023Post Tags:Uromigos Live 2023-Bladder Cancer
Related Posts
Dr. Powles chaired a livestreamed RCC session that included lively discussion from Drs. Atkins, McDermott, and Rini.
The panel highlights a serious of relevant studies in renal cell carcinoma, including CONTACT-03 and TiNivo-2.
The panel discusses data related to RLTs in prostate cancer, including a recap of the VISION trial and the PSMAfore trial.
The panel breaks down the details of the PROpel, TALAPRO-2, and MAGNITUDE trials along with relevant rPFS and HR data.
The panel discussed the latest updates in NMIBC, including relevant data pertaining to pembro, atezo, and more.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.